Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
Always utilize sterile Bacteriostatic Water as your primary diluent for in-vitro assays
VEGFR2 activation angiogenesis newly formed blood vessels at the injured site supply of oxygen, nutrients, immune cells
GLOW 70 is a research-grade peptide matrix formulated to leverage the pleiotropic synergy of three distinct signaling molecules
Even peptides with short half-lives can leave metabolic traces in the body that trigger a positive result on advanced panels
